Opening book details…
Can I read Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations on EtoBox?
Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations by Martin Regensburger; Chi Wang Ip; Zacharias Kohl; Christoph Schrader; Peter P. Urban; Jan Kassubek; Wolfgang H. Jost is a Neuroscience article available to read on EtoBox.
What is Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations about?
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson’s disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions. Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson’s disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
Who reads Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations?
It is typically read by researchers, students, and practitioners in Neuroscience.
- Author
- Martin Regensburger; Chi Wang Ip; Zacharias Kohl; Christoph Schrader; Peter P. Urban; Jan Kassubek; Wolfgang H. Jost
- Publisher
- Springer Science and Business Media LLC
- Published
- 2023
- Language
- EN
- Field
- Neuroscience (Life Sciences)